PARTNERSHIP FOR AFRICAN VACCINE MANUFACTURING (PAVM)
‘FROM ASPIRATION TO ACTION’

PROGRESS MADE SO FAR ON IMPLEMENTING THE PARTNERSHIPS FOR VACCINE MANUFACTURING IN AFRICA

OBJECTIVES

I. Update on progress made so far on the Partnership for African Vaccine Manufacturing in Africa
II. Agree on an AU-endorsed approach to facilitate regulatory approval of vaccines produced in Africa
III. Discuss critical market shaping needs once African countries produce vaccines
IV. Build on the momentum of vaccine manufacture hubs and pilot a drug API-final drug product Hub program

EXPECTED OUTCOMES

1. Align on the recommendation for AU regulatory approach including how to strengthen AMA. AMA has successfully reach the ratification threshold with 15 countries signing.
2. Align on the recommendations for a pooled procurement mechanism for vaccine manufacturing industry in Africa.
3. Provide insights into the program that has been developed in each PAVM workstream.
4. A soft launch of the Framework For Action
5. Reach the required number of ratifications to bring the AMA Treaty into Force.

Co-convened by:

• Africa Centres for Disease Control and Prevention (Africa CDC)
• African Medicines Agency (AMA)
• African Union Development Agency NEPAD (AUDI NEPAD)
• Continental Free Trade Area (CFTA)

Kigali Serena Hotel, Kigali, Rwanda

DATE AND TIME

Monday 6th December 2021
10.00 AM - 07.00PM (GMT+2)

Thursday 07th December 2021
10.00 AM - 07.00PM (GMT+2)

You can stream the event live on our social media pages:

www.facebook.com/africacdc
www.youtube.com/c/AfricaCDC

FOR INQUIRIES PLEASE CONTACT:

Dr. Nicaise Ndembri, Head of Science Office: NicaiseN@africa-union.org
Dr. Chrys Promesse Kaniki, Public Health Analyst: KanikiC@africa-union.org
Ezinne V.C Onwuekwe, Vaccine Coordinator: OnwuekweE@africa-union.org